Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Ovarian cancer exhibits frequent genetic and epigenetic alterations in homologous recombination repair (HRR) pathway genes.
• HRR deficiency leads to genomic instability and reliance on alternative DNA repair pathways.
• This deficiency correlates with increased sensitivity to DNA-damaging agents, including platinum analogues and PARP inhibitors.

Purpose of the Study:

• To review DNA repair pathway alterations in ovarian cancer.
• To discuss current and emerging therapeutic strategies targeting the DNA damage response and repair in ovarian cancer.

Main Methods:

• Literature review of genomic studies in ovarian cancer.
• Analysis of DNA repair pathway alterations.
• Discussion of therapeutic approaches including chemotherapy and PARP inhibitors.

Main Results:

• Genomic studies reveal significant alterations in HRR pathway genes in ovarian cancer.
• HRR deficiency is a key feature driving genomic instability and therapeutic sensitivity.
• Platinum analogues and poly(adenosine diphosphate)-ribose polymerase (PARP) inhibitors are effective in HRR-deficient ovarian cancer.

Conclusions:

• Understanding DNA repair alterations is crucial for ovarian cancer treatment.
• Targeting DNA damage response pathways offers promising therapeutic strategies.
• Chemotherapy and PARP inhibitors represent key treatments for HRR-deficient ovarian cancer.